logo-loader
viewColt Resources

Colt Resources to conduct regional exploration program at Montemor

no_picture_pai.jpg

Colt Resources (CVE:GTP) (OTCQX:COLTF) announced Monday the results of an NI 43-101 compliant technical report for the company's Montemor gold project in Portugal, recommending a regional exploration program at the property.

The project is located in the Alentejo Region, east of the city of Lisbon, and has historical resource estimates that range from  150koz to 550koz gold.

The report, conducted by SRK Consulting, concluded that there is potential to expand this historical resource to a range of 8-12 million tonnes grading an average of 2.5 to 3.0 g/t gold.

"The potential to extend both the strike length and down-dip extension of known mineralized zones, as well as the discovery of new host structures and potential mineralized zones beneath cover exists," the company said in a statement.

Colt said it plans to undertake a regional exploration program to identify up to six new targets for drilling by the third quarter of this year. In addition, SRK recommended that Colt also conduct a resource expansion campaign across the known mineralized zones through infill and step out drill programs.

"Colt's team looks forward to working closely with SRK Exploration Services in the design and execution of an extensive exploration strategy aimed at unlocking the exceptional potential we feel exists on the Boa Fe shear zone," said Colt president and CEO Nikolas Perrault.

"It seems that historical work has only focused on a small portion of what appears to be a significant regional system."

The NI 43-101 compliant technical report for Montemor has now been filed on Sedar and is also available on the company's website at www.coltresources.com .

Quick facts: Colt Resources

Price: 0 0

TSX-V:P01
Market: TSX-V
Market Cap: £0.00
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

'The clinical benefits of Clevegen have now been demonstrated' Faron Pharma CEO

Faron Pharmaceuticals Oy's (LON:FARN) Markku Jalkanen caught up with Proactive London's Andrew Scott to discuss the recently released Matins trial update which is assessing the firm's drug Clevegen. He says feedback from the dose escalation study confirmed Clevegen has good tolerability...

2 minutes ago

2 min read